27 October 2022 | Other

Merck CEO will take charge of the company’s chairman

On Wednesday, the company Merck & Co announced that Ken Frazier leaves the post of chairman. He will be replaced by Chief Executive Officer Rob Davis, who has taken on extra responsibilities on December 1.

Frazier joined the company nearly 30 years ago, and over the years, he was helping the company to stay among the leaders in the drug production field.

He was steering the company during the difficult lawsuit related to the painkiller Vioxx, which was withdrawn from the market. He also played a pivotal role in the acquisition of US drug product manufacturer Schering-Plough. In 2009 the company received the possibility to sell the drug Keytruda. Then, this drug became Merck's best-selling product. 



Company MarketCheese
Period: 01.10.2026 Expectation: 4750 pips
Sell silver amid Fed’s hawkish stance
Today at 10:32 AM 1
Period: 14.09.2026 Expectation: 135 pips
Buy SPX on strong tech reports
Today at 06:28 AM 13
Period: 28.09.2026 Expectation: 4000 pips
Buy USDCAD while US inflation remains sticky
28 August 2026 57
Period: 11.08.2026 Expectation: 740 pips
Go long on Brent crude up to $95
28 August 2026 51
Period: 27.09.2026 Expectation: 4650 pips
Invest in USDJPY up to its all-time high of 164.00
27 August 2026 55
Period: 30.09.2026 Expectation: 500 pips
Sell ​​GBPUSD down to 1.3540
27 August 2026 36
Go to forecasts